IN8bio Announces Major Advancements in Leukemia and Glioblastoma Treatments
On October 12, 2023, IN8bio, a pioneering clinical-stage biopharmaceutical company, made a significant announcement regarding its gamma-delta T cell therapies. The company has successfully completed the enrollment for its Phase 1 study of INB-100, a potential treatment for leukemia patients. This marks a significant step forward as INB-100 is being evaluated for its safety when […]